ProCE Banner Activity

Follicular Lymphoma Treatment Landscape and EZH2 Inhibition in Relapsed/Refractory Disease


Download this slideset from a live symposium for an expert overview of the current treatment landscape in follicular lymphoma, along with the latest clinical data and future directions in EZH2 inhibition in the setting of relapsed/refractory disease.

Released: December 07, 2023



Sonali M. Smith

Sonali M. Smith, MD, FASCO

Elwood V. Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
The University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from Genentech, a member of the Roche Group; Genmab; Ipsen Biopharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc.

Genentech, a member of the Roche Group


Ipsen Biopharmaceuticals Inc

Regeneron Pharmaceuticals, Inc